Asteria Health recalled 1,464 testosterone pellets on January 26, 2026, due to potential metal particulate contamination. The recall affects products distributed nationwide. Consumers must stop using the product immediately and seek guidance from healthcare providers.
Presence of Foreign substance - potential presence of metal particulate matter
Consumers and healthcare providers should stop using this product immediately. Contact F.H. INVESTMENTS, Inc. (dba Asteria Health) or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves Testosterone 100mg Anastrozole 4mg sterile pellets. The affected lot numbers include 254000105, 254000110, 254000112, and 254000113, with expiration dates ranging from May 28, 2026, to September 26, 2026.
The product may contain foreign metal particulate matter, posing a risk of serious health issues. This contamination has a high hazard level, necessitating immediate action.
As of the report date, no specific incidents or injuries have been documented related to this recall.
Consumers should cease using the recalled pellets immediately. Contact F.H. INVESTMENTS, Inc. for guidance and further instructions regarding the return process.
For more information, reach F.H. INVESTMENTS, Inc. at their facility in Birmingham, AL. Visit the FDA's recall page for updates: https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0331-2026.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.